{
    "clinical_study": {
        "@rank": "129249", 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the efficacy and safety of autologous\n      transplantation of Adipose Tissue derived Mesenchymal stem cells (MSCs) in patient with\n      critical limb ischemia"
        }, 
        "brief_title": "Safety and Effect of Adipose Tissue Derived Mesenchymal Stem Cells Implantation in Patients With Critical Limb Ischemia", 
        "completion_date": {
            "#text": "April 2011", 
            "@type": "Actual"
        }, 
        "condition": "Critical Limb Ischemia", 
        "condition_browse": {
            "mesh_term": "Ischemia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  At least 6 months since the onset CLI(Chronic ASO or Buerger disease)\n\n          -  Patients with luminal stenosis > 50% by leg angiography\n\n          -  Age is between 20 and 80\n\n          -  Patients whose Rutherford's class is II-4, III-5 or III-6 (Patients with rest pain or\n             ischemic ulcer/necrosis)\n\n          -  Patients for whom angioplasty and bypass surgery are not indicated because of\n             anatomical or procedural reasons or frequent reocclusion/restenosis following\n             traditional revascularization\n\n          -  Patients who can give informed consent themselves in writing\n\n        Exclusion Criteria:\n\n          -  Previous or current history of neoplasm or comorbidity that could impact the\n             patient's survival\n\n          -  Detection of proximal source of emboli including atrial fibrillation\n\n          -  Primary hematologic disease, including hypercoagulable states\n\n          -  Detection of proliferative retinopathy\n\n          -  Entrapment syndrome\n\n          -  Alcohol abuse, cocaine amphetamine etc.\n\n          -  Detection of osteomyelitis\n\n          -  Uncontrolled DM"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 8, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01663376", 
            "org_study_id": "KSC-MSCs-CLI"
        }, 
        "intervention": {
            "description": "Intramuscular injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 1x10e8 ~3x10e8 cells", 
            "intervention_name": "Autologous Adipose Tissue derived MSCs Transplantation", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 24, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Pusan", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Pusan National University Hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "Effects of Adipose Tissue Derived Stem Cells Implantation in Patients With Critical Limb Ischemia", 
        "overall_official": {
            "affiliation": "Pusan National University Hospital", 
            "last_name": "Han Cheol Lee, M.D. & Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "March 2010", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "To evaluate the change of treated critical limb ischemia before cell implantation and at 3, 6, 12 months post injection of MSCs", 
            "measure": "Major Adverse Events Analysis (MAEs)", 
            "safety_issue": "Yes", 
            "time_frame": "48 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01663376"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "results_reference": {
            "PMID": "22498564", 
            "citation": "Lee HC, An SG, Lee HW, Park JS, Cha KS, Hong TJ, Park JH, Lee SY, Kim SP, Kim YD, Chung SW, Bae YC, Shin YB, Kim JI, Jung JS. Safety and effect of adipose tissue-derived stem cell implantation in patients with critical limb ischemia: a pilot study. Circ J. 2012;76(7):1750-60. Epub 2012 Apr 12."
        }, 
        "secondary_outcome": [
            {
                "description": "To evaluate the change of treated critical limb ischemia before cell implantation and at 3, 6, 12 months post injection of MSCs.", 
                "measure": "Ankle-Brachial Index (ABI)", 
                "safety_issue": "No", 
                "time_frame": "48 weeks"
            }, 
            {
                "description": "To evaluate the change of treated critical limb ischemia before cell implantation and at 3, 6, 12 months post injection of MSCs.", 
                "measure": "Digital subtraction angiography (DSA)", 
                "safety_issue": "No", 
                "time_frame": "48 weeks"
            }, 
            {
                "description": "To evaluate the change of treated critical limb ischemia before cell implantation and at 3, 6, 12 months post injection of MSCs.", 
                "measure": "Thermography", 
                "safety_issue": "No", 
                "time_frame": "48 weeks"
            }, 
            {
                "description": "To evaluate the change of treated critical limb ischemia before cell implantation and at 3, 6, 12 months post injection of MSCs.", 
                "measure": "Wong-Baker FACES Pain Rating Score", 
                "safety_issue": "No", 
                "time_frame": "48 weeks"
            }, 
            {
                "description": "To evaluate the change of treated critical limb ischemia before cell implantation and at 3, 6, 12 months post injection of MSCs.", 
                "measure": "Treadmill test", 
                "safety_issue": "No", 
                "time_frame": "48 weeks"
            }
        ], 
        "source": "K-Stemcell Co Ltd", 
        "sponsors": {
            "collaborator": {
                "agency": "Pusan National University Hospital", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "K-Stemcell Co Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2009", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}